Literature DB >> 28716861

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.

Isabelle Krämer1, Stephan Stilgenbauer2, Sascha Dietrich1, Sebastian Böttcher3,4, Matthias Zeis5, Michael Stadler6, Jörg Bittenbring7, Lutz Uharek8, Christof Scheid9, Ute Hegenbart1, Anthony Ho1, Michael Hallek9, Michael Kneba3, Norbert Schmitz5, Hartmut Döhner2, Peter Dreger1.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 28716861     DOI: 10.1182/blood-2017-04-775841

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  23 in total

1.  Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis.

Authors:  Almuth Hoffmann; Sascha Dietrich; Susanne Hain; Michael Rieger; Ute Hegenbart; Leopold Sellner; Anthony D Ho; Carsten Müller-Tidow; Peter Dreger
Journal:  Haematologica       Date:  2019-01-10       Impact factor: 9.941

Review 2.  How and when I do allogeneic transplant in CLL.

Authors:  John G Gribben
Journal:  Blood       Date:  2018-05-11       Impact factor: 22.113

3.  Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.

Authors:  Mauricette Michallet; Peter Dreger; Mohamad Sobh; Linda Koster; Jennifer Hoek; Ariane Boumendil; Christof Scheid; Christopher P Fox; Gerald Wulf; William Krüger; Michel van Gelder; Paolo Corradini; Domenico Russo; Jakob Passweg; Hélène Schoemans; Wolfgang Bethge; Nicolaas Schaap; Jan Cornelissen; Paul Browne; Nadira Durakovic; Lutz Muller; Silvia Montoto; Nicolaus Kroger; Johannes Schetelig
Journal:  Bone Marrow Transplant       Date:  2019-11-07       Impact factor: 5.483

4.  Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.

Authors:  Niels Smedegaard Andersen; Martin Bornhäuser; Martin Gramatzki; Peter Dreger; Antonin Vitek; Michal Karas; Mauricette Michallet; Carol Moreno; Michel van Gelder; Anja Henseler; Liesbeth C de Wreede; Stefan Schönland; Nicolaus Kröger; Johannes Schetelig
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-29       Impact factor: 4.553

5.  Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation.

Authors:  M Rovira; N Villamor; F Cobo; F Fernández-Aviles; M L López-Guerra; F Guijarro; T Baumann; E Montserrat
Journal:  Bone Marrow Transplant       Date:  2020-03-20       Impact factor: 5.483

6.  Relapsed disease and aspects of undetectable MRD and treatment discontinuation.

Authors:  Barbara Eichhorst; Moritz Fürstenau; Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

7.  Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Authors:  Othman Al-Sawaf; Carmen Diana Herling; Udo Holtick; Christoph Scheid; Paula Cramer; Stephanie Sasse; Bastian von Tresckow; Armin Tuchscherer; Kirsten Fischer; Barbara Eichhorst; Michael Hallek; Lukas P Frenzel
Journal:  Haematologica       Date:  2019-02-21       Impact factor: 9.941

8.  PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.

Authors:  Peter Dreger; Anna Sureda; Kwang Woo Ahn; Mary Eapen; Carlos Litovich; Herve Finel; Ariane Boumendil; Ajay Gopal; Alex F Herrera; Christoph Schmid; José Luis Diez-Martin; Ephraim Fuchs; Javier Bolaños-Meade; Mahasweta Gooptu; Monzr M Al Malki; Luca Castagna; Stefan O Ciurea; Alida Dominietto; Didier Blaise; Fabio Ciceri; Johanna Tischer; Paolo Corradini; Silvia Montoto; Stephen Robinson; Zafer Gülbas; Mehdi Hamadani
Journal:  Blood Adv       Date:  2019-02-12

Review 9.  Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy.

Authors:  Jacob S Appelbaum; Filippo Milano
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

10.  Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Authors:  Wael Saber; Jennifer R Brown; Haesook T Kim; Kwang Woo Ahn; Zhen-Huan Hu; Matthew S Davids; Virginia O Volpe; Joseph H Antin; Mohamed L Sorror; Mazyar Shadman; Oliver Press; Joseph Pidala; William Hogan; Robert Negrin; Steven Devine; Joseph Uberti; Edward Agura; Richard Nash; Jayesh Mehta; Joseph McGuirk; Stephen Forman; Amelia Langston; Sergio A Giralt; Miguel-Angel Perales; Minoo Battiwalla; Gregory A Hale; Robert Peter Gale; David I Marks; Mehdi Hamadani; Sid Ganguly; Ulrike Bacher; Hillard Lazarus; Ran Reshef; Gerhard C Hildebrandt; Yoshihiro Inamoto; Jean-Yves Cahn; Melhem Solh; Mohamed A Kharfan-Dabaja; Nilanjan Ghosh; Ayman Saad; Mahmoud Aljurf; Harry C Schouten; Brian T Hill; Attaphol Pawarode; Tamila Kindwall-Keller; Nakhle Saba; Edward A Copelan; Sunita Nathan; Amer Beitinjaneh; Bipin N Savani; Jan Cerny; Michael R Grunwald; Jean Yared; Baldeep M Wirk; Taiga Nishihori; Saurabh Chhabra; Richard F Olsson; Asad Bashey; Usama Gergis; Uday Popat; Ronald Sobecks; Edwin Alyea
Journal:  Clin Cancer Res       Date:  2019-06-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.